BIDOLI, PAOLO
 Distribuzione geografica
Continente #
NA - Nord America 493
EU - Europa 184
AS - Asia 78
AF - Africa 9
SA - Sud America 6
OC - Oceania 2
Totale 772
Nazione #
US - Stati Uniti d'America 480
IT - Italia 62
DE - Germania 45
AT - Austria 24
CN - Cina 19
TR - Turchia 13
GB - Regno Unito 11
CA - Canada 10
HK - Hong Kong 10
JP - Giappone 10
IN - India 9
IE - Irlanda 7
VN - Vietnam 7
EG - Egitto 6
RU - Federazione Russa 5
UA - Ucraina 5
BE - Belgio 4
CZ - Repubblica Ceca 4
CL - Cile 3
ES - Italia 3
FR - Francia 3
NL - Olanda 3
FI - Finlandia 2
ID - Indonesia 2
MX - Messico 2
RO - Romania 2
SG - Singapore 2
TW - Taiwan 2
ZA - Sudafrica 2
AU - Australia 1
BN - Brunei Darussalam 1
BR - Brasile 1
CO - Colombia 1
EC - Ecuador 1
GH - Ghana 1
GR - Grecia 1
HN - Honduras 1
IQ - Iraq 1
IR - Iran 1
NZ - Nuova Zelanda 1
PL - Polonia 1
PT - Portogallo 1
SI - Slovenia 1
TH - Thailandia 1
Totale 772
Città #
Santa Cruz 88
Fairfield 33
Ashburn 26
Vienna 24
Milan 21
Buffalo 20
Seattle 19
Houston 17
Woodbridge 13
Cambridge 12
Wilmington 11
San Diego 10
Ann Arbor 9
Chicago 8
Frankfurt am Main 8
Mountain View 8
Boardman 7
Beijing 6
Cairo 6
Provo 6
Rome 6
University Park 6
Central 5
Dong Ket 5
Los Angeles 5
Redmond 5
Toronto 5
Fleming Island 4
Guangzhou 4
Istanbul 4
Las Vegas 4
London 4
Naples 4
Brooklyn 3
Clearwater 3
Dublin 3
Saint Petersburg 3
Shanghai 3
Wuhan 3
Adana 2
Andover 2
Ankara 2
Annone di Brianza 2
Bengaluru 2
Bergamo 2
Bologna 2
Brussels 2
Bussolengo 2
Büdelsdorf 2
Calgary 2
Ciudad Lopez Mateos 2
Dallas 2
Helsinki 2
Henderson 2
Induno Olona 2
Isparta 2
Jakarta 2
Madison 2
Meerut 2
Muizenberg 2
Mumbai 2
Oklahoma City 2
Palo Alto 2
Portland 2
Princeton 2
Reston 2
Riva 2
San Francisco 2
Scranton 2
Singapore 2
Tokyo 2
Winston-Salem 2
Ōita 2
Aisai 1
Alpignano 1
Amsterdam 1
Athens 1
Auburn 1
Austin 1
Avellino 1
Bagnacavallo 1
Borgo San Giovanni 1
Burbank 1
Böblingen 1
Celâl 1
Changsha 1
Cologne 1
Columbus 1
Crugers 1
Darmstadt 1
Düsseldorf 1
Ercolano 1
Fremont 1
Ghaziabad 1
Gijón 1
Guayaquil 1
Haarlem 1
Hamilton 1
Hebei 1
Hillsboro 1
Totale 526
Nome #
Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab, file e39773b7-8650-35a3-e053-3a05fe0aac26 147
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma, file e39773b6-5ef4-35a3-e053-3a05fe0aac26 106
A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the “Real Life” Population And Actual Dose, file e39773b2-26d7-35a3-e053-3a05fe0aac26 82
Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study., file e39773b4-fce4-35a3-e053-3a05fe0aac26 74
Liquid biopsy testing can improve selection of advanced non-small-cell lung cancer patients to rechallenge with gefitinib, file e39773b7-864d-35a3-e053-3a05fe0aac26 55
Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer, file e39773b7-8fb9-35a3-e053-3a05fe0aac26 55
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer, file e39773b7-864c-35a3-e053-3a05fe0aac26 51
Focus on nivolumab in NSCLC, file e39773b7-8fbb-35a3-e053-3a05fe0aac26 43
Second-line erlotinib or intermittent erlotinib plus docetaxel in male ex-smokers with squamous NSCLC: The TALISMAN randomized trial, file e39773b7-8651-35a3-e053-3a05fe0aac26 42
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer, file e39773b7-8fba-35a3-e053-3a05fe0aac26 42
Novel cytotoxic chemotherapies in small cell lung carcinoma, file e39773b7-6dd6-35a3-e053-3a05fe0aac26 41
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations, file e39773b7-864f-35a3-e053-3a05fe0aac26 35
Treatment with gefitinib in elderly patients or patients with poor performance status (PS) affected with non small cell lung carcinoma (NSCLC) [Trattamento con Gefitinib nei pazienti anziani o con scarso performance status (PS), affetti da carcinoma polmonare non a piccole cellule (NSCLC)], file 69ec8715-4f64-4345-8137-8ee898490b78 7
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial, file d1eff57f-dde1-430c-9051-a81a74929618 2
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial, file e39773b6-4d56-35a3-e053-3a05fe0aac26 2
[Radiologic examination in assessing the response to chemoradiotherapy of esophageal spinocellular carcinoma], file e39773b5-dedf-35a3-e053-3a05fe0aac26 1
Small cell lung cancer, file e39773b5-dee2-35a3-e053-3a05fe0aac26 1
Phase III trial comparing 3-6months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: Safety and compliance in the TOSCA trial, file e39773b5-f087-35a3-e053-3a05fe0aac26 1
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer, file e39773b5-f1e2-35a3-e053-3a05fe0aac26 1
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial, file e39773b5-fa8a-35a3-e053-3a05fe0aac26 1
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients, file e39773b6-03bc-35a3-e053-3a05fe0aac26 1
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study, file e39773b6-2b2f-35a3-e053-3a05fe0aac26 1
FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer, file e39773b6-2d38-35a3-e053-3a05fe0aac26 1
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial, file e39773b8-5979-35a3-e053-3a05fe0aac26 1
Totale 793
Categoria #
all - tutte 1387
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1387


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/20185 0000 00 00 0014
2018/201935 5121 42 24 4334
2019/202028 3033 01 28 0341
2020/2021110 3722 73 52 16281520
2021/2022275 10101116 2116 1712 12248739
2022/2023317 28327452 911 2124 1823250
Totale 793